District court patent filings are back down to roughly double the number of Patent Trial and Appeal Board (PTAB) filings, with 65 new complaints to the PTAB’s 28 new inter partes reviews (IPRs) and one post grant review (PGR). The complaints were driven by the Rothschild entities, adding defendants to existing campaigns, and a fair number of pharmaceutical complaints.
Recent Posts
- CAFC Reverses Indefiniteness Ruling Since Claims Meet ‘Demanding’ Standard for Judicial Correction
- The Personal Side of Patents: The Battle for Life-Saving Drugs | IPWatchdog Unleashed
- CAFC Majority Reverses PTAB Obviousness Ruling Over Dissent, But Rule 36 Issues Persist for CPC Patent
- Liability Risks Before the UPC: How U.S. Companies Need to Prepare
- Other Barks & Bites for Friday, November 7: CJEU Action Against EU Commission Referred Over SEP Regulation; Ninth Circuit Affirms CoComelon Copyright Win; and C4IP Urges USTR to Address IP Concerns in USMCA Joint Review